Practice Area Focus
- Development Strategy
- Regulatory Strategy
- Clinical Trial Design
Gordon Francis joined NDA Partners as an Expert Consultant in 2014. Dr. Francis is an expert in the area of neurology and neuro-immunology, with an emphasis on the treatment of Multiple Sclerosis (MS). Following
a Neuro-Immunology fellowship at UCSF, in 1983 he returned to McGill University in Montreal and headed the MS Clinical Research Clinic as well as the Clinical Research Center at the Montreal Neurological Institute. Prior to moving to the pharmaceutical industry in 1998, he conducted extensive research in MS as a clinical investigator for various sponsoring companies.
Since moving to industry, he has served as Vice President of Global Neurology Product Development for Serono, Inc., and served in similar roles at Elan Pharmaceuticals, Inc., and Novartis. During his long career, he became experienced in all phases of clinical development, liaised extensively with research and business development groups, interacted frequently with regulatory agencies globally (US, Europe, Australia, Canada, Japan), and in addition provided medical support to commercial and medical affairs groups within the companies for which he worked.
As a recognized expert in neurology, Dr Francis has published over 100 peer reviewed articles in the field. Among his many achievements, he
has headed teams which led to the regulatory approval of Rebif in US, Tysabri for MS in US, Europe and other countries and most recently world-wide approval of fingolimod in MS, the first oral therapy for MS.